Creo Medical (CREO:AIM) is aiming to bring forward its US commercial launch plans after its medical device Speedboat RS2 was approved by the US Food and Drug Administration in only 49 days. The approval for the disposable device for the treatment of colorectal cancer is six months ahead of schedule and could bode well for future product ...